**Core Concept**
Pneumocystis jiroveci pneumonia (PCP) is a life-threatening opportunistic infection primarily affecting immunocompromised individuals, such as those with HIV/AIDS or undergoing chemotherapy. The treatment of PCP involves the use of antimicrobial agents that target the organism's unique biochemical pathways.

**Why the Correct Answer is Right**
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment for PCP due to its synergistic mechanism of action. TMP inhibits dihydrofolate reductase, an enzyme essential for the synthesis of tetrahydrofolate, which is necessary for DNA synthesis and function in Pneumocystis jiroveci. SMX, a sulfonamide, competitively inhibits dihydropteroate synthase, an enzyme involved in the synthesis of tetrahydrofolate. This dual inhibition effectively blocks the organism's ability to produce tetrahydrofolate, ultimately leading to the death of the organism.

**Why Each Wrong Option is Incorrect**
* **Option A:** Pentamidine is an alternative treatment option for PCP, but it is not the first-line choice due to its higher toxicity and lower efficacy compared to TMP-SMX.
* **Option B:** Corticosteroids, such as prednisone, are used adjunctively to prevent respiratory complications in patients with PCP, but they are not a primary treatment for the infection.
* **Option D:** Fluconazole, an antifungal agent, is not effective against Pneumocystis jiroveci and is not used in the treatment of PCP.

**Clinical Pearl / High-Yield Fact**
TMP-SMX is contraindicated in patients with a history of severe hypersensitivity reactions to the drug or its components, as well as in those with certain types of anemia, such as megaloblastic anemia.

**Correct Answer:** C. Trimethoprim-sulfamethoxazole